Curative Effect of Butylphthalide and Edaravone Dexborneol in Acute Ischemic Cerebrovascular Disease
Objective To investigate the effectiveness of Butylphthalide Injection and Edaravone Dexborneol in acute ischemic stroke(AIS)treatment.Methods Clinical data from eighty-six patients with AIS admitted to Siping Central People's Hospital in Jilin Province from January 2022 to February 2024 were retrospectively selected.They were di-vided into a control group(treated with butylphthalein injection)and a study group(treated with butylphthalein injec-tion combined with edaravone and dexmedetomidine)according to different medication methods,with forty-three pa-tients in each group.The clinical efficacy,and neurological function status of the two groups were compared and ana-lyzed.Results After treatment,the total effective rate of the study group was 95.35%(41/43),which was higher than 79.07%(34/43)of the control group,and the differences was statistically significant(χ2=5.108,P=0.024).Before treat-ment,there were no statistically significant differences between the two groups in terms of the Chinese Stroke Scale(CSS)and Modified Rankin Scale(mRS)scores(both P>0.05).After treatment,the scores of both groups of patients significantly decreased,and the CSS and mRS scores of the study group were lower than those of the control group,the differences were statistically significant(all P<0.05).Conclusion In the treatment of AIS patients,the combination of butylphthalein and edaravone dexmedetomidine can further improve the neurological function damage of patients,and the therapeutic effect is good.
NETL
NSTL
万方数据
